M&T Bank Corp Inhibrx, Inc. Transaction History

M&T Bank Corp

$28.6 Billion
Q1 2024

A detailed history of M&T Bank Corp transactions in Inhibrx, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 21,476 shares of INBX stock, worth $304,314. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,476

Previous 23,843 9.93%

Holding current value

$304,314

Previous $906,000 17.22%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$32.76 - $39.56 $77,542 - $93,638	-2,367 Reduced 9.93%	21,476 $750,000
Q4 2023 Feb 06, 2024	SELL	$14.5 - $38.0 $67,613 - $177,194	-4,663 Reduced 16.36%	23,843 $906,000
Q3 2023 Nov 02, 2023	BUY	$15.75 - $26.31 $1,606 - $2,683	102 Added 0.36%	28,506 $523,000
Q2 2023 Aug 09, 2023	BUY	$16.96 - $27.82 $111,936 - $183,612	6,600 Added 30.27%	28,404 $737,000
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $73,578 - $108,234	3,988 Added 22.38%	21,804 $411,000

Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $38,281 - $63,227	1,897 Added 7.01%	28,965 $713,000
Q4 2022 Feb 13, 2023	SELL	$20.18 - $33.33 $224,986 - $371,596	-11,149 Reduced 38.49%	17,816 $438,000
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $70,684 - $150,951	-6,104 Reduced 18.4%	27,068 $486,000
Q2 2022 Aug 05, 2022	BUY	$8.52 - $25.26 $182,575 - $541,296	21,429 Added 182.48%	33,172 $376,000
Q1 2022 May 09, 2022	BUY	$19.89 - $43.18 $19,392 - $42,100	975 Added 9.05%	11,743 $262,000
Q4 2021 Feb 07, 2022	SELL	$26.75 - $46.02 $22,202 - $38,196	-830 Reduced 7.16%	10,768 $470,000
Q3 2020 Nov 06, 2020	BUY	$16.77 - $20.65 $194,498 - $239,498	11,598 New	11,598 $209,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account